Disrupted Healthcare – 19 Deals and Investments This Week

VC Deals (10 deals, $140M)

Theracos Inc., a Marlborough, Mass.-based developer of drugs to treat Type II diabetes, has raised $25 million in new equity and debt funding. No investor information was disclosed

 ZipLine Medical Inc., a Campbell, Calif.-b ased developer of noninvasive surgical skin closure devices, has raised $19 million in new VC funding. MVM Life Science Partners led the round, and was joined by return backer China Materialia LLC

Greatist, a provider of health and wellness content to millennials, has raised $4.5 million in Series A funding. Floodgate led the round, and was joined by individual angels

BioTheranostics, a San Diego-based developer of molecular diagnostics for cancer, has raised $32 million in new funding. MVM Life Science Partnersled the round, and was joined by Canepa Advanced Healthcare Fund and HealthQuest Capital. The deal results in BioTheranostics spinning out of BioMérieux (Paris: BIM), which will remain a minority shareholder

Vasopharm, a German developer of therapeutics for the treatment of cerebrovascular diseases, has raised €20 million in new VC funding. Fort Rock Capital was joined by return backers Entrepreneurs Fund, Heidelberg Capital Private Equity, Bayern Kapital and Hanseatic Asset Management

Akili Interactive Labs Inc., a Boston-based developer of digital medicines for cognitive assessment and personalized treatment, has raised $30.5 million in new VC funding. Backers include JAZZ Venture Partners, Canepa Advanced Healthcare Fund and PureTech Health

BookDoc, a months-old, Kuala Lumpur-based startup that connects patients to a network of doctors in Southeast Asia (a la ZocDoc), has raised a seed round that includes a $2 million investment from Prince Abdul Qawi, a member of The House of Bolkiah, the ruling family of Brunei

Mucosis, a nine-year-old, Groningen, Netherlands-based clinical-stage biotechnology company at work on a vaccine for RSV, a virus that theatens newborns and elderly adults, has raised 3.7 million euros ($4 million) from Wellcome Trust

Zoctr Health, an India startup which sells home healthcare packages by aggregating different services, raised an undisclosed amount of money from the Times Group today. This is its third round of funding in the last nine months. Before this, it raised US$1 million in July 2015 and an undisclosed amount of seed funding in April 2015

Mumbai based menstrual hygiene startup Saral Designs has raised angel funding from investors in Powai Valley, including Farooq Adam, founder of Fynd, and Ambi Parameswaran, former CEO of FCB Ulka Advertising

PE Deals (2 deals)

Arsenal Capital Partners has acquired a majority stake inBioreclamationIVT, a Westbury, N.Y.-based provider of biological and in vitro products to biopharma, diagnostic and biotech organizations

Bioclinica, a Newtown, Penn.-based provider of clinical trials services, has acquired Clinverse Inc., a Raleigh, N.C.-based provider of financial lifecycle automation solutions for the clinical trials market. No financial terms were disclosed. Sellers included Edison Partners and Hatteras Venture Partners. BioClinica shareholders include Ampersand Capital Partners, JLL Partners and Water Street Healthcare Partners

IPO Deals (4 deals)

AveXis Inc., a Dallas-based developer of gene therapies for patients with severe genetic and orphan diseases like spinal muscular atrophy, has filed for a $115 million IPO. It plans to trade on the Nasdaq under ticker symbol AVXS, with Goldman Sachs and Jefferies serving as lead underwriters. Shareholders in the pre-revenue company include PBM Capital (15% pre-IPO stake), Deerfield Management (9.9%), JDH Investment Management (9.5%), Roche Finance (8.4%), White Rock Capital Partners (6.6%), Third Security (6.6%), T. Rowe Price (5.4%), Venrock (5.3%), Janus Capital Management, Adage Capital Management, RA Capital Management, QVT Financial, Rock Springs Capital Management, Foresite Capital Management, RTW Investments and Boxer Capital. AveXis has raised over $75 million in VC funding

Oncobiologics, a Cranbury, N.J.-based developer of biosimilar therapeutics, has filed for a $115 million IPO. It plans to trade on the Nasdaq under ticker symbol ONS, with Jefferies and Barclays serving as lead underwriters. The company has raised over $43 million in VC funding, from firms like Perceptive Advisors,Cormorant Global Healthcare Master Fund, Longwood Capital Partners, venBio Select Fund, Proximare Lifesciences Fund, OSSB Pharma Fund and MIH Fund

PLX Pharma Inc., a Houston-based developer of an oral drug delivery system that is designed to increase safety and efficacy, has set its IPO terms to 3.8 million shares being offered at between $17 and $19 per share. It would have an initial market cap of around $169 million, were it to price in the middle of its range. The company plans to trade on the Nasdaq under ticker symbol PLXP, with Maxim Group serving as sole underwriter. Shareholders include Integra Venture (6.6% pre-IPO stake) and Aurus Bios Fondo de Inversion Privado (6.3%)

BeiGene Ltd., a Beijing-based developer of immune-oncology therapeutics, has set its IPO terms to 5.5 million American depository shares being offered at between $22 and $24 per share. It plans to trade on the Nasdaq under ticker symbol BGNE, with Goldman Sachs, Morgan Stanley and Cowen & Co. serving as lead underwriters. The company reports a $15.8 million net loss on $2.8 million in revenue for the first six months of 2015. BeiGene has raised over $170 million in VC funding from Baker Brothers Life Sciences (25.8% pre-IPO stake), Hillhouse Capital (9.9%), Merck Sharp & Dohme Research (7.7%) and CTIC Capital Partners (6.4%)

Other Deals (3 deals)

GlaxoSmithKline (LSE: GSK) is in talks withQualcomm (Nasdaq: QCOM) over a $1 billion joint venture to develop medical technologies

Questis, a Charleston, S.C.-based employee wellness platform, has raised $2.3 million in venture debt funding from firms like Capital A Partners

Parexel International Corp. (Nasdaq: PRXL) has agreed to acquire Health Advances LLC, a Weston, Mass.-based life sciences strategy consulting firm. No financial terms were disclosed for the deal, which was managed by Clearsight Advisors

Sources: Term Sheet, Financial Times, StrictlyVC, TechinAsia, CrunchBase, TechCrunch, Bloomberg

The Propell Group

#healthtech #asia